Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency.

Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, Pellier I, Durieu I, Perlat A, Royer B, Le Quellec A, Jeziorski E, Fischer A, Lortholary O; CEREDIH French PID study group, Aaron L, Adoue D, Aguilar C, Aladjidi N, Alcais A, Amoura Z, Arlet P, Armari-Alla C, Bader-Meunier B, Bayart S, Bertrand Y, Bienvenu B, Blanche S, Bodet D, Bonnotte B, Borie R, Boutard P, Briandet C, Brion JP, Brouard J, Cohen-Beaussant S, Costes L, Couderc LJ, Cougoul P, Courteille V, de Saint Basile G, Devoldere C, Deville A, Donadieu J, Dore E, Dulieu F, Edan C, Entz-Werle N, Fieschi C, Forestier A, Fouyssac F, Gajdos V, Galicier L, Gandemer V, Gardembas M, Gaud C, Guillerm G, Hachulla E, Hamidou M, Hermine O, Hoarau C, Humbert S, Jaccard A, Jacquot S, Jais JP, Jaussaud R, Jeandel PY, Kebaili K, Korganow AS, Lambotte O, Lanternier F, Larroche C, Lascaux AS, Le Moigne E, Le Moing V, Lebranchu Y, Lecuit M, Lefevre G, Lemal R, Te VLT, Marie-Cardine A, Silva NM, Masseau A, Massot C, Mazingue F, Merlin E, Michel G, Millot F, Monlibert B, Monpoux F, Moshous D, Mouthon L, Munzer M, Neven B, Nove-Josserand R, Oksenhendler E, Ouachée-Chardin M, Oudot C, Pagnier A, Pasquali JL, Pasquet M, Perel Y, Picard C, Piguet C, Plantaz D, Provot J, Quartier P, Rieux-Laucat F, Roblot P, Roger PM, Rohrlich PS, Rubie H, Salle V, Sarrot-Reynauld F, Servettaz A, Stephan JL, Schleinitz N, Suarez F, Swiader L, Taque S, Thomas C, Tournilhac O, Thumerelle C, Tron F, Vannier JP, Viallard JF.

J Clin Immunol. 2019 Oct;39(7):702-712. doi: 10.1007/s10875-019-00658-9. Epub 2019 Aug 10.

PMID:
31401750
2.

[Immunotherapy of cancers by inhibiting control of the immune response honored by a Nobel Prize].

Lebranchu Y.

Rev Prat. 2019 Mar;69(3):243-246. Review. French. No abstract available.

PMID:
30983244
3.

Intravenous Immunoglobulins in the Prevention of Rejection of a Second or Third Kidney Graft.

Glotz D, Rostaing L, Merville P, Squifflet JP, Lebranchu Y.

Transplant Proc. 2018 Jan - Feb;50(1):70-71. doi: 10.1016/j.transproceed.2017.11.010.

PMID:
29407334
4.

Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.

Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, Morelon E, Malvezzi P, Parissiadis A, Tourret J, Guidicelli G, Sayegh J, Mousson C, Grimbert P, Top I, Le Quintrec M, Purgus R, Westeel PF, Proust B, Chabot V, Lebranchu Y, Dehaut F, Büchler M.

Transplantation. 2018 Apr;102(4):688-698. doi: 10.1097/TP.0000000000002002.

PMID:
29135832
5.

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.

Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, Bruneval P, Glotz D, Legendre C, Empana JP, Jouven X, Segev DL, Montgomery RA, Zeevi A, Halloran PF, Loupy A.

J Am Soc Nephrol. 2018 Feb;29(2):620-635. doi: 10.1681/ASN.2017050589. Epub 2017 Oct 17.

6.

Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.

Gatault P, Kamar N, Büchler M, Colosio C, Bertrand D, Durrbach A, Albano L, Rivalan J, Le Meur Y, Essig M, Bouvier N, Legendre C, Moulin B, Heng AE, Weestel PF, Sayegh J, Charpentier B, Rostaing L, Thervet E, Lebranchu Y.

Am J Transplant. 2017 May;17(5):1370-1379. doi: 10.1111/ajt.14109. Epub 2017 Jan 3.

7.

Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.

Forconi C, Gatault P, Miquelestorena-Standley E, Noble J, Al-Hajj S, Guillemain R, Stern M, Hoffmann T, Prat L, Suberbielle C, Masson E, Cesbron-Gautier A, Gaudy-Graffin C, Goudeau A, Thibault G, Ivanes F, Guibon R, Kazma I, Lebranchu Y, Büchler M, Magnan A, Halimi JM, Baron C.

J Heart Lung Transplant. 2017 Mar;36(3):315-324. doi: 10.1016/j.healun.2016.08.014. Epub 2016 Aug 26.

PMID:
27751774
8.

Genome-Wide Association Study of Acute Renal Graft Rejection.

Ghisdal L, Baron C, Lebranchu Y, Viklický O, Konarikova A, Naesens M, Kuypers D, Dinic M, Alamartine E, Touchard G, Antoine T, Essig M, Rerolle JP, Merville P, Taupin JL, Le Meur Y, Grall-Jezequel A, Glowacki F, Noël C, Legendre C, Anglicheau D, Broeders N, Coppieters W, Docampo E, Georges M, Ajarchouh Z, Massart A, Racapé J, Abramowicz D, Abramowicz M.

Am J Transplant. 2017 Jan;17(1):201-209. doi: 10.1111/ajt.13912. Epub 2016 Jul 22.

9.

Unexpected impairment of TNF-α-induced maturation of human dendritic cells in vitro by IL-4.

Chabot V, Martin L, Meley D, Sensebé L, Baron C, Lebranchu Y, Dehaut F, Velge-Roussel F.

J Transl Med. 2016 Apr 14;14:93. doi: 10.1186/s12967-016-0848-2.

10.

[Not Available].

Lebranchu Y.

Bull Acad Natl Med. 2016 Feb;200(2):285-290. No abstract available.

PMID:
29898324
11.

One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.

Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y.

Transplantation. 2016 Feb;100(2):391-9. doi: 10.1097/TP.0000000000000958.

PMID:
26555944
12.

CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.

Thibault G, Paintaud G, Legendre C, Merville P, Coulon M, Chasseuil E, Ternant D, Rostaing L, Durrbach A, Di Giambattista F, Büchler M, Lebranchu Y.

Transpl Int. 2016 Feb;29(2):184-95. doi: 10.1111/tri.12688. Epub 2015 Oct 8.

13.

Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation.

Gatault P, Bertrand D, Büchler M, Colosio C, Hurault de Ligny B, Weestel PF, Rerolle JP, Thierry A, Sayegh J, Moulin B, Snanoudj R, Rivalan J, Heng AE, Sautenet B, Lebranchu Y.

Transpl Int. 2016 Jan;29(1):41-50. doi: 10.1111/tri.12656.

14.

New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity.

Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y.

Drugs. 2014 Sep;74(14):1605-34. doi: 10.1007/s40265-014-0277-6. Review. Erratum in: Drugs. 2014 Dec;74(18):2217.

15.

IL-2 phosphorylates STAT5 to drive IFN-γ production and activation of human dendritic cells.

Herr F, Lemoine R, Gouilleux F, Meley D, Kazma I, Heraud A, Velge-Roussel F, Baron C, Lebranchu Y.

J Immunol. 2014 Jun 15;192(12):5660-70. doi: 10.4049/jimmunol.1300422. Epub 2014 May 14.

16.

Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?

Gatault P, Lebranchu Y.

Transplant Res. 2013 Nov 20;2(Suppl 1):S3. doi: 10.1186/2047-1440-2-S1-S3. Epub 2013 Nov 20.

17.

[Orientation of the immune response of the epithelium: epithelial cells, dendritic cells and lymphocytes].

Lebranchu Y.

Bull Acad Natl Med. 2014 Jan;198(1):9-16. French. No abstract available.

PMID:
26259282
18.

Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients.

Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, Paintaud G.

Pharmacogenet Genomics. 2014 Jan;24(1):26-34. doi: 10.1097/FPC.0000000000000017.

PMID:
24322002
19.

Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study.

Chaigne B, Gatault P, Darrouzain F, Barbet C, Degenne D, François M, Szymanski P, Rabot N, Golea G, Diot E, Maillot F, Lebranchu Y, Nivet H, Paintaud G, Halimi JM, Guillevin L, Büchler M.

Clin Exp Immunol. 2014 May;176(2):172-9. doi: 10.1111/cei.12246.

20.

Progression of pulse pressure in kidney recipients durably exposed to CsA is a risk factor for epithelial phenotypic changes: an ancillary study of the CONCEPT trial.

Xu-Dubois YC, Hertig A, Lebranchu Y, Hurault de Ligny B, Thervet E, Jauréguy M, Touchard G, Le Pogamp P, Le Meur Y, Toupance O, Heng AE, Bayle F, Girardot-Seguin S, Servais A, Meas-Yedid V, Rondeau E.

Transpl Int. 2014 Apr;27(4):344-52. doi: 10.1111/tri.12253. Epub 2014 Jan 28.

21.

Risk factors for impaired CD4+ T-cell reconstitution following rabbit antithymocyte globulin treatment in kidney transplantation.

Longuet H, Sautenet B, Gatault P, Thibault G, Barbet C, Marliere JF, Halimi JM, Lebranchu Y, Baron C, Büchler M.

Transpl Int. 2014 Mar;27(3):271-9. doi: 10.1111/tri.12249. Epub 2013 Dec 27.

22.

Mycophenolic acid-treated dendritic cells generate regulatory CD4+ T cells that suppress CD8+ T cells' allocytotoxicity.

Kazma I, Lemoine R, Herr F, Chadet S, Meley D, Velge-Roussel F, Lebranchu Y, Baron C.

Int Immunol. 2014 Mar;26(3):173-81. doi: 10.1093/intimm/dxt054. Epub 2013 Nov 12.

PMID:
24222014
23.

Pretransplant identification of acute rejection risk following kidney transplantation.

Lebranchu Y, Baan C, Biancone L, Legendre C, Morales JM, Naesens M, Thomusch O, Friend P.

Transpl Int. 2014 Feb;27(2):129-38. doi: 10.1111/tri.12205. Epub 2013 Oct 25. Review.

24.

Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch.

Gatault P, Jollet I, Paintaud G, Magdelaine C, Bridoux F, Lebranchu Y, Büchler M, Touchard G, Thierry A.

Hum Immunol. 2013 Dec;74(12):1616-8. doi: 10.1016/j.humimm.2013.08.278. Epub 2013 Aug 29. Erratum in: Hum Immunol. 2015 Mar;76(2-3):206. Philippe, Gatault [corrected to Gatault, Philippe]; Isabelle, Jollet [corrected to Jollet, Isabelle]; Gilles, Paintaud [corrected to Paintaud, Gilles]; Charlotte, Magdelaine [corrected to Magdelaine, Charlotte];Franck, Bridoux [corrected to Bridoux, Franck.

PMID:
23994588
25.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

26.

CMV infection in the donor and increased kidney graft loss: impact of full HLA-I mismatch and posttransplantation CD8(+) cell reduction.

Gatault P, Halimi JM, Forconi C, Thibault G, Barbet C, Mérieau E, Gaudy-Graffin C, Marlière JF, Goudeau A, Bruyère F, Lebranchu Y, Büchler M, Baron C.

Am J Transplant. 2013 Aug;13(8):2119-29. doi: 10.1111/ajt.12298. Epub 2013 Jun 3.

27.

The Orai-1 and STIM-1 complex controls human dendritic cell maturation.

Félix R, Crottès D, Delalande A, Fauconnier J, Lebranchu Y, Le Guennec JY, Velge-Roussel F.

PLoS One. 2013 May 20;8(5):e61595. doi: 10.1371/journal.pone.0061595. Print 2013.

28.

Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial.

Zimmermann H, Choquet S, Moore J, Salles G, Morschhauser F, Lamy T, Jaccard A, Horst HA, Leithäuser M, Dührsen U, Reinke P, Lebranchu Y, Neuhaus R, Lehmkuhl H, Tarella C, Schlattmann P, Riess H, Leblond V, Trappe RU.

Leukemia. 2013 Oct;27(10):2102-5. doi: 10.1038/leu.2013.110. Epub 2013 Apr 15. No abstract available.

29.

Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial.

Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, Ternant D, Foulon C, Pilorge B, Lemay D, Sung C, Halimi JM, Baron C, Lebranchu Y.

Transpl Immunol. 2013 Mar;28(2-3):120-6. doi: 10.1016/j.trim.2013.03.001. Epub 2013 Mar 16.

PMID:
23507258
30.

Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.

Caillard S, Porcher R, Provot F, Dantal J, Choquet S, Durrbach A, Morelon E, Moal V, Janbon B, Alamartine E, Pouteil Noble C, Morel D, Kamar N, Buchler M, Mamzer MF, Peraldi MN, Hiesse C, Renoult E, Toupance O, Rerolle JP, Delmas S, Lang P, Lebranchu Y, Heng AE, Rebibou JM, Mousson C, Glotz D, Rivalan J, Thierry A, Etienne I, Moal MC, Albano L, Subra JF, Ouali N, Westeel PF, Delahousse M, Genin R, Hurault de Ligny B, Moulin B.

J Clin Oncol. 2013 Apr 1;31(10):1302-9. doi: 10.1200/JCO.2012.43.2344. Epub 2013 Feb 19.

PMID:
23423742
31.

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C.

Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62. doi: 10.2215/CJN.04760512. Epub 2013 Jan 10.

32.

Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and attempt to reconcile discrepancies.

Zuber J, Grimbert P, Blancho G, Thaunat O, Durrbach A, Baron C, Lebranchu Y.

Nephrol Dial Transplant. 2013 May;28(5):1100-11. doi: 10.1093/ndt/gfs570. Epub 2012 Dec 21. Review.

PMID:
23262436
33.

Renal function of renal transplantation patients after hospitalization in an intensive care unit.

Badin J, Longuet H, Guillon A, Barbet C, Halimi JM, Lebranchu Y, Perrotin D, Buchler M.

Transplant Proc. 2012 Nov;44(9):2792-4. doi: 10.1016/j.transproceed.2012.09.027.

PMID:
23146526
34.

The role of Thymoglobulin induction in kidney transplantation: an update.

Mourad G, Morelon E, Noël C, Glotz D, Lebranchu Y.

Clin Transplant. 2012 Sep-Oct;26(5):E450-64. doi: 10.1111/ctr.12021. Review.

PMID:
23061755
35.

Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey.

Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, Thumerelle C, Oksenhendler E, Boutboul D, Thomas C, Hoarau C, Lebranchu Y, Stephan JL, Cazorla C, Aladjidi N, Micheau M, Tron F, Baruchel A, Barlogis V, Palenzuela G, Mathey C, Dominique S, Body G, Munzer M, Fouyssac F, Jaussaud R, Bader-Meunier B, Mahlaoui N, Blanche S, Debré M, Le Bourgeois M, Gandemer V, Lambert N, Grandin V, Ndaga S, Jacques C, Harre C, Forveille M, Alyanakian MA, Durandy A, Bodemer C, Suarez F, Hermine O, Lortholary O, Casanova JL, Fischer A, Picard C.

Medicine (Baltimore). 2012 Jul;91(4):e1-19. doi: 10.1097/MD.0b013e31825f95b9.

36.

New sampling strategy using a Bayesian approach to assess iohexol clearance in kidney transplant recipients.

Benz-de Bretagne I, Le Guellec C, Halimi JM, Gatault P, Barbet C, Alnajjar A, Büchler M, Lebranchu Y, Andres CR, Vourcʼh P, Blasco H.

Ther Drug Monit. 2012 Jun;34(3):289-97. doi: 10.1097/FTD.0b013e31824a6534.

PMID:
22585184
37.

Kidney transplant with multiple renal artery grafts from deceased donors: are long-term graft and patient survival compromised?

Laouad I, Bretagnol A, Fabre E, Halimi JM, Al-Najjar A, Boutin JM, Bruyère F, Nivet H, Lebranchu Y, Büchler M.

Prog Transplant. 2012 Mar;22(1):102-9.

PMID:
22489451
38.

Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study.

Lebranchu Y, Snanoudj R, Toupance O, Weestel PF, Hurault de Ligny B, Buchler M, Rerolle JP, Thierry A, Moulin B, Subra JF, Deteix P, Le Pogamp P, Finzi L, Etienne I.

Am J Transplant. 2012 Jul;12(7):1801-10. doi: 10.1111/j.1600-6143.2012.04036.x. Epub 2012 Apr 5.

39.

Kidney transplantation in an elite HIV controller: limited impact of immunosuppressive therapy on viro-immunological status.

Lambotte O, Lecuroux C, Saez-Cirion A, Barbet C, Shin SY, Boufassa F, Bastides F, Lebranchu Y.

J Infect. 2012 Jun;64(6):630-3. doi: 10.1016/j.jinf.2012.03.001. Epub 2012 Mar 6. No abstract available.

PMID:
22406689
40.

Renal resistive index as a new independent risk factor for new-onset diabetes mellitus after kidney transplantation.

Mutinelli-Szymanski P, Caille A, Tranquart F, Al-Najjar A, Büchler M, Barbet C, Marlière JF, Gatault P, Réault J, Boin C, Chatelet V, Laouad I, Nivet H, Lebranchu Y, Halimi JM.

Transpl Int. 2012 Apr;25(4):464-70. doi: 10.1111/j.1432-2277.2012.01445.x. Epub 2012 Feb 24.

41.

Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas.

Caillard S, Lamy FX, Quelen C, Dantal J, Lebranchu Y, Lang P, Velten M, Moulin B; French Transplant Centers.

Am J Transplant. 2012 Mar;12(3):682-93. doi: 10.1111/j.1600-6143.2011.03896.x. Epub 2012 Jan 6.

42.

Correction of postkidney transplant anemia reduces progression of allograft nephropathy.

Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, Glowacki F, Moulin B, Lebranchu Y, Touchard G, Jaureguy M, Pallet N, Le Meur Y, Rostaing L, Martinez F; CAPRIT study Investigators.

J Am Soc Nephrol. 2012 Feb;23(2):360-8. doi: 10.1681/ASN.2011060546. Epub 2011 Dec 22.

43.

Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency.

Chandesris MO, Azarine A, Ong KT, Taleb S, Boutouyrie P, Mousseaux E, Romain M, Bozec E, Laurent S, Boddaert N, Thumerelle C, Tillie-Leblond I, Hoarau C, Lebranchu Y, Aladjidi N, Tron F, Barlogis V, Body G, Munzer M, Jaussaud R, Suarez F, Clément O, Hermine O, Tedgui A, Lortholary O, Picard C, Mallat Z, Fischer A.

Circ Cardiovasc Genet. 2012 Feb 1;5(1):25-34. doi: 10.1161/CIRCGENETICS.111.961235. Epub 2011 Nov 14. Erratum in: Circ Cardiovasc Genet. 2012 Aug 1;5(4):e37.

PMID:
22084479
44.

Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.

Le Meur Y, Thierry A, Glowacki F, Rerolle JP, Garrigue V, Ouali N, Heng AE, Delahousse M, Albano L, Lang P, Couzi L, Jaureguy M, Lebranchu Y, Mousson C, Glotz D, Kessler M, Vrtovsnik F, Rouanet S, Tagieva N, Kamar N.

Transplantation. 2011 Dec 15;92(11):1244-51. doi: 10.1097/TP.0b013e318234e134.

PMID:
22067312
45.

Doubling of serum creatinine in clinical trials, cost-effectiveness studies, and individual patients: adequate use in renal transplantation.

Gatault P, Al-Najjar A, Barbet C, Roland M, Laouad I, Buchler M, Marlière JF, Métais PE, Clément A, Nivet H, Lebranchu Y, Halimi JM.

Transplantation. 2011 Nov 15;92(9):1012-7. doi: 10.1097/TP.0b013e31823015e4.

PMID:
21941225
46.

Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine.

Joannidès R, Monteil C, de Ligny BH, Westeel PF, Iacob M, Thervet E, Barbier S, Bellien J, Lebranchu Y, Seguin SG, Thuillez C, Godin M, Etienne I.

Am J Transplant. 2011 Nov;11(11):2414-22. doi: 10.1111/j.1600-6143.2011.03697.x. Epub 2011 Sep 19.

47.

Mothers without HLA antibodies before transplantation have a low risk of alloimmunization post-transplantation.

Gatault P, Jollet I, Rabot N, Boulanger MD, Taupin JL, Barbet C, Baron C, Thierry A, Halimi JM, Lebranchu Y, Touchard G, Büchler M.

Tissue Antigens. 2011 Oct;78(4):241-8. doi: 10.1111/j.1399-0039.2011.01757.x.

PMID:
21929572
48.

Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study.

Lebranchu Y, Thierry A, Thervet E, Büchler M, Etienne I, Westeel PF, Hurault de Ligny B, Moulin B, Rérolle JP, Frouget T, Girardot-Seguin S, Toupance O.

Am J Transplant. 2011 Aug;11(8):1665-75. doi: 10.1111/j.1600-6143.2011.03637.x.

49.

Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor.

Vuiblet V, Birembaut P, François A, Cordonnier C, Noel LH, Goujon JM, Paraf F, Machet MC, Girardot-Seguin S, Lebranchu Y, Rieu P.

Nephrol Dial Transplant. 2012 Jan;27(1):411-6. doi: 10.1093/ndt/gfr261. Epub 2011 May 26.

PMID:
21617191
50.

Response to questions regarding the design and results of the IMPACT trial.

Humar A; IMPACT Investigators Steering Committee, Peeters P, Abramowicz D, Humar A, Lebranchu Y, Hauser I, Jardine A, Limaye AP, Vincenti F, Punch JD, Blumberg E.

Am J Transplant. 2011 Jan;11(1):177-8. doi: 10.1111/j.1600-6143.2010.03370.x. No abstract available.

Supplemental Content

Loading ...
Support Center